deCODE genetics: Predicting the probability of death
PR90161
REYKJAVIK, Iceland, June 18, 2021 /PRNewswire=KYODO JBN/ --
Scientists from deCODE genetics have developed a predictor based on protein
measurements in blood samples that predicts the time to all-cause death
better than traditional risk factors.
In a paper published today in Communications Biology, scientists from deCODE
genetics, a subsidiary of Amgen, describe how they developed predictor of how
much is left of the life of a person.
Using a dataset of ~5000 protein measurements in 22,913 Icelanders, of whom
7,061 died during the study period, the scientists developed a predictor of
the time to death that can outperform predictors based on multiple known risk
factors. The predictor can identify the 5% at highest risk in a group of 60-80
year olds, where 88% died within ten years and the 5% at lowest risk where only
1% died within ten years.
The scientists explored how individual proteins associate with mortality and
various causes of death and found most causes of death to have similar protein
profiles. In particular, they found growth/differentiation factor 15 (GDF15),
which has been associated with mortality and ageing before, to be an important
predictor of all-cause mortality. Furthermore, they found that, on average,
participants predicted at high risk of death within a short period of time had
less grip strength and performed worse on an exercise tolerance test and a test
of cognitive function than those predicted at lower risk.
"The predictor gives a good estimate of general health from a single blood
draw," says Thjodbjorg Eiriksdottir scientist at deCODE genetics and author on
the paper.
"This is pretty cool but also scary and hopefully somewhat useful", says Kari
Stefansson a senior author on the paper . "This shows that our general health
is reflected in the plasma proteome. Using just one blood sample per person you
can easily compare large groups in a standardized way, for example, to estimate
treatment effects in clinical trials."
Based in Reykjavik, Iceland, deCODE is a global leader in analyzing and
understanding the human genome. Using its unique expertise in human genetics
combined with growing expertise in transcriptomics and population proteomics
and vast amount of phenotypic data, deCODE has discovered risk factors for
dozens of common diseases and provided key insights into their pathogenesis.
The purpose of understanding the genetics of disease is to use that information
to create new means of diagnosing, treating and preventing disease. deCODE is a
wholly-owned subsidiary of Amgen (NASDAQ: AMGN).
Contact:
Thora Kristin Asgeirsdottir
PR and Communications
deCODE genetics
thoraa@decode.is
354 894 1909
Photo - https://mma.prnewswire.com/media/1535463/deCODE_genetics.jpg
Logo - https://mma.prnewswire.com/media/1535464/deCODE_genetics_Amgen_Logo.jpg
Source: deCODE genetics
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。